Prognostic evaluation of systemic inflammation indexes in Psoriasis patients.

• Grant number: 25/03296-5
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: September 01, 2025
• End date: August 31, 2026
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Hélio Amante Miot
• Grantee: Maria Cecília Valsechi Belli
• Host Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

INTRODUCTION: Psoriasis is a systemic inflammatory disease associated with comorbidities and the production of inflammatory cytokines. The blood count reflects the activity of different compartments of the bone marrow, which respond to different cytokines. Several authors have identified alterations in the blood count in patients with psoriasis compared to healthy controls. To date, no prognostic aspects of these indicators have been evaluated in relation to the response to immunobiologicals.OBJECTIVE: To describe and analyze the patterns of systemic inflammation markers in patients with psoriasis vulgaris treated with immunobiologicals at Unesp. METHOD: Retrospective cohort study evaluating the medical records of patients treated with immunobiologicals at the Psoriasis Outpatient Clinic of the Hospital das Clínicas da Faculdade de Medicina de Botucatu (HCFMB-UNESP) between 2012 and 2025. The study will include 100 male and female patients with psoriasis vulgaris and/or psoriatic arthritis, aged between 18 and 80 years. Eligible participants' recent blood count records will be evaluated, as well as records from the consultation prior to the introduction of immunobiological treatment. The SII will be calculated using the formula: neutrophils x platelets/lymphocytes and the Neutrophil-Lymphocyte (NLR), Monocyte-Lymphocyte (MLR) and Platelet-Lymphocyte (PLR) ratios will also be determined. The Pan-Immuno-Inflammatory Value (PIV) will be calculated using the formula: neutrophils x platelets x monocytes/lymphocytes. The main outcome will be the association between a favorable clinical assessment, therefore the absence of psoriatic lesions and arthritis on the day of the consultation, their medications and the biomarkers assessed by the blood count. Demographic data such as gender, age, weight, family history, medications in use, disease severity, PASI and associated arthritis will be collected from the medical records. The markers will be compared between the immunobiological groups and by clinical outcomes using generalized linear models. It is expected to identify changes between inflammatory markers and disease activity, as well as exploring their usefulness in predicting subgroups with a better response to different immunobiologicals.